Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * * NEWS 1 Web Page for STN Seminar Schedule - N. America NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals

NEWS 3 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded IPC version 2007.01 thesaurus available on STN NEWS 4 JAN 16 NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data NEWS 6 JAN 22 CA/CAplus updated with revised CAS roles CA/CAplus enhanced with patent applications from India NEWS 7 JAN 22 PHAR reloaded with new search and display fields NEWS 8 JAN 29 NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers RUSSIAPAT enhanced with pre-1994 records NEWS 11 FEB 15 NEWS 12 KOREAPAT enhanced with IPC 8 features and functionality FEB 23 NEWS 13 FEB 26 MEDLINE reloaded with enhancements NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE NEWS 16 IFICDB/IFIPAT/IFIUDB reloaded with enhancements FEB 26 NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format NEWS 19 MAR 16 CASREACT coverage extended NEWS 20 MAR 20 MARPAT now updated daily NEWS 21 MAR 22 LWPI reloaded RDISCLOSURE reloaded with enhancements NEWS 22 MAR 30 NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records NEWS 26 APR 30 CA/CAplus enhanced with 1870-1889 U.S. patent records NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN NEWS 28 MAY 01 New CAS web site launched NEWS 29 MAY 08 CA/CAplus Indian patent publication number format defined NEWS 30 MAY 11 RDISCLOSURE on STN Easy enhanced with new search and display fields NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS LOGIN Welcome Banner and News Items NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:56:05 ON 14 MAY 2007

| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

=> file req

FILE 'REGISTRY' ENTERED AT 14:56:26 ON 14 MAY 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6 DICTIONARY FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10760493.str

L1STRUCTURE UPLOADED

≃> d 11 L1 HAS NO ANSWERS L1 STR



G1 O, N

Structure attributes must be viewed using STN Express query preparation.

0 ANSWERS

=> s ll sss sam SAMPLE SEARCH INITIATED 14:57:12 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -11 TO ITERATE 100.0% PROCESSED 11 ITERATIONS SEARCH TIME: 00.00.01 FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE** PROJECTED ITERATIONS: 22 ТО 418 PROJECTED ANSWERS: 0 ТО 0 L2 O SEA SSS SAM L1 => s l1 full FULL SEARCH INITIATED 14:57:17 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -229 TO ITERATE 229 ITERATIONS 100.0% PROCESSED 23 ANSWERS SEARCH TIME: 00.00.01 L3 23 SEA SSS FUL L1

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 172.55 | 172.76 |

FILE 'CAPLUS' ENTERED AT 14:57:22 ON 14 MAY 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 May 2007 VOL 146 ISS 21 FILE LAST UPDATED: 13 May 2007 (20070513/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 L4

=> d bib abs hitstr 1-3 14

3 L3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

- AN 2006:366398 CAPLUS
- DN 145:283680
- ТΤ Improving drug discovery from microorganisms
- Farnet, Chris M .: Zazopoulos, Emmanuel AU
- cs
- Ecopia BioSciences Inc., Montreal, OC, Can. Natural Products (2000, 95-106. Editor(s): Zhang, Lixin; Demain, Arnold L. Publisher: Humana Press Inc., Totowa, N. J. so CODEN: 69HZZ2; ISBN: 1-58829-383-1

in u. ntors

Conference; General Review DT

LΑ English

AB A review. Microorganisms remain unrivalled in their ability to produce bioactive small mols. for drug development. However, the core technologies used to discover microbial natural products have not evolved significantly over the past several decades, resulting in a shortage of new drug leads. Advances in DNA-sequencing and bioinformatics technologies now make it possible to rapidly identify the clusters of genes that encode bioactive compds. and to make computer predictions of chemical structure based on gene sequence information. These structure predictions can be used to identify new chemical entities and provide important physicochem. "handles" that guide compound purification and structure confirmation. Industrialization of this process provides a model for improving the efficiency of natural-product discovery. The application of advanced genomics and bioinformatics technologies is now poised to revolutionize natural-product discovery and lead a renaissance of interest in microorganisms as a source of bioactive compds. for drug development. ΤТ 735316-93-5, ECO 02301 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ECO 02301; application of advanced genomics and bioinformatics


technol. lead to development of antifungal ECO-02301 from S. aizunensis at Ecopia and evidenced microorganism as source for natural bioactive compound for drug development) 735316-93-5 CAPLUS

RN


2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, CN 56-amino-29-[(6-deoxy- α -L-mannopyranosyl)oxy]-15, 17, 33, 35, 37, 41, 43, 45, 47, 51, 53-undecahydroxy-N-(2-hydroxy-5-oxo-1cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.


Currently available stereo shown.



Currently available stereo shown.



GI



AB This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivs., and to methods for obtaining the compds. One method of obtaining these compds. is by cultivation of novel strains of Streptomyces aizunensis shown to produce polyketide I; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compds., to the use of these compds. and their pharmaceutically acceptable salts and derivs. as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. I has in vivo Candida albicans antifungal activity similar to a dose of 0.25 mg/kg of fungizone and increases 4-fold the median survival time of infected mice. I is also effective against all the human tumor cell lines that have been assayed in the NCI screening panel, suggesting a broad anticancer activity against several types of human cancer; the GI50 calculated for all cell lines was lower than 10^{+} 10-6M, and in some cases reached the nanomolar or picomolar level. The invention also relates to pharmaceutical compns. comprising these novel polyketides or a pharmaceutically acceptable salts or derivs. thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides. The biosynthetic locus for production of I in S. aizunensis strain NRRL B-11277 spans .apprx.176,000 bp of DNA and encodes 38 proteins.

IT 735316-93-5P


RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(polyene polyketides, processes for their production using polyketide synthetase genes and enzymes from Streptomyces aizunensis, and their use as fungicidal and antitumor pharmaceutical)

RN 735316-93-5 CAPLUS

CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown. Currently available stereo shown.





56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1cyclopenten-1-yl)-14,16,30-trimethyl-31-[(phenylmethyl)imino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown. Currently available stereo shown.




(CA

15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown. Currently available stereo shown.













RN 735317-01-8 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-15,17,29,33,35,37,41,43,45,47,51,53-dodecahydroxy-N-(2-hydroxy-5oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Double bond geometry unknown. Currently available stereo shown.







ş

.

Double bond geometry unknown. Currently available stereo shown.


.





RN

735317-07-4 CAPLUS 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[(aminoiminomethyl)amino]-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME) CN



:


OH OHOH


PAGE 1-B


RN 735317-09-6 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide,

29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,5 3-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-56-[[(4-nitrophenyl)methyl]amino]-31-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown.








PAGE 1-D




RN 735317-10-9 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-(cyclohexylamino)-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown. Currently available stereo shown. •

PAGE 1-A




PAGE 1-B




PAGE 1-Ċ

RN 735317-11-0 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-(acetylamino)-29-[(6-deoxy-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.





PAGE 1-B



RN 735317-12-1 CAPLUS

CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-56-[(2-methyl-1-oxopropyl)amino]-31-oxo- (9CI) (CA INDEX NAME)








 $\begin{array}{c} 0 \\ -C - Pr - i \\ -CH = CH - C - NH \\ 0 \\ 0 \\ 0 \end{array}$


RN 735317-13-2 CAPLUS CN Benzamide, N-[28-[(6-deoxy-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

٠



PAGE 1-B





- RN
- 735317-14-3 CAPLUS Benzamide, N-[28-[(6-deoxy-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-nitro-(9CI) (CA INDEX NAME) CN

Absolute stereochemistry. Double bond geometry unknown.

PAGE 1-A OH Мe Мe H N, ö ЬH ÒН ò

PAGE 1-B






hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-hydroxy-(9CI) (CA INDEX NAME)


•

Absolute stereochemistry. Double bond geometry unknown.






PAGE 1-B



PAGE 1-C




PAGE 1-D

OH


RN 735317-17-6 CAPLUS Benzenepropanamide, α-amino-N-[28-[(6-deoxy-α-Lmannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown. ,

PAGE 1-A











PAGE 1-D



RN 735317-18-7 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-29-[(6-deoxy-α-Lmannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)









OH Me OH Me

RN 735317-19-8 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,5 3-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-56-[[(2S)-2-pyrrolidinylcarbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown.

PAGE 1-A







PAGE 1-C




RN 735317-20-1 CAPLUS CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[[(2S)-2-amino-3-hydroxy-1-oxopropyl]amino]-29-[(6-deoxy-α-Lmannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-(9CI) (CA INDEX NAME)





PAGE 1-C



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:56:05 ON 14 MAY 2007)

| | FILE | 'REGISTRY' ENTERED AT 14:56:26 ON 14 MAY 2007 | |
|----|------|---|--|
| L1 | | STRUCTURE UPLOADED | |
| L2 | | O S L1 SSS SAM | |
| L3 | • | 23 S L1 FULL | |
| | | | |

FILE 'CAPLUS' ENTERED AT 14:57:22 ON 14 MAY 2007 L4 3 S L3